SANES

10.81

+0.52%↑

BBVA

20.12

+0.68%↑

BNP

92.84

+0.12%↑

CABK

11.665

-0.3%↓

INGA

27.065

-0.44%↓

SANES

10.81

+0.52%↑

BBVA

20.12

+0.68%↑

BNP

92.84

+0.12%↑

CABK

11.665

-0.3%↓

INGA

27.065

-0.44%↓

SANES

10.81

+0.52%↑

BBVA

20.12

+0.68%↑

BNP

92.84

+0.12%↑

CABK

11.665

-0.3%↓

INGA

27.065

-0.44%↓

SANES

10.81

+0.52%↑

BBVA

20.12

+0.68%↑

BNP

92.84

+0.12%↑

CABK

11.665

-0.3%↓

INGA

27.065

-0.44%↓

SANES

10.81

+0.52%↑

BBVA

20.12

+0.68%↑

BNP

92.84

+0.12%↑

CABK

11.665

-0.3%↓

INGA

27.065

-0.44%↓

Home・Stock List・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Open

SectorFinance

171.1 -0.47

Buy Sell

Overview

Share price change

24h

Current

Min

170

Max

173.6

Key metrics
By Trading Economics
Income	41M 88M
Sales	-11M 762M
P/E Sector Avg	57.428 58.236
EPS	1.17
Profit margin	11.569
Employees	10,456
EBITDA	26M 225M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+36.5% upside

Dividends
By Dow Jones
Next Earnings	23 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-2.7B 15B
Previous open	171.57
Previous close	171.1

News Sentiment

By Acuity

21%

79%

46 / 438 Finance

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

25 May 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 May 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 May 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 May 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 May 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 May 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 May 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 May 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 May 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 May 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 May 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 May 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 May 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 May 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 May 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 May 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 May 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 May 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 May 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 May 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 May 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 May 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

36.5% upside

12 Months Forecast

Average 233 EUR 36.5%

High 262 EUR

Low 210 EUR

Based on 8 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Sartorius Stedim Biotech. - Dist in the past 3 months.

Sentiment

By Acuity

46 / 438 Finance

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.